{
    "Trade/Device Name(s)": [
        "HAVAb IgG II",
        "HAVAb IgG II Reagent Kit",
        "HAVAb IgG II Calibrator",
        "HAVAb IgG II Controls"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K222850",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113704"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JIS",
        "QCH"
    ],
    "Summary Letter Date": "September 19, 2022",
    "Summary Letter Received Date": "September 21, 2022",
    "Submission Date": "August 9, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.3310",
        "21 CFR 862.1150",
        "21 CFR 866.3920"
    ],
    "Regulation Name(s)": [
        "Hepatitis A Virus (HAV) Serological Assays",
        "Clinical Chemistry Test Systems: Calibrator",
        "Assayed quality control material for clinical microbiology assays"
    ],
    "Analyte Class(es)": [
        "serology",
        "immunology",
        "microbiology"
    ],
    "Analyte(s)": [
        "IgG antibody to hepatitis A virus (IgG anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Sodium heparin tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Dipotassium EDTA tube",
        "Tripotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Alinity i system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)",
        "Automated immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Serological detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for HAVAb IgG II CMIA assay for qualitative detection of IgG anti-HAV in serum and plasma on Alinity i system",
    "Indications for Use Summary": "Qualitative detection of IgG antibody to hepatitis A virus (IgG anti-HAV) in human serum and plasma from adults and pediatric patients (4-21 years), to determine immune status for HAV infection; not for diagnosis of acute HAV or donor screening.",
    "fda_folder": "Microbiology"
}